MEI Pharma (MEIP)
NASDAQ:MEIP

MEI Pharma (MEIP) Income Statement

958 Followers

MEI Pharma Income Statement

Last quarter (Q1 2023), MEI Pharma's total revenue was $8.73M, an increase of 12.54% from the same quarter last year. In Q1, MEI Pharma's net income was $-16.62M. See MEI Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
$ 41.67M$ 40.70M$ 34.80M$ 27.76M$ 4.92M$ 1.62M
Cost of Revenue
-$ 0.00$ 1.41M$ 2.67M$ 4.26M$ 3.38M
Gross Profit
$ 32.94M$ 40.70M$ 33.39M$ 25.09M$ 652.00K$ -1.76M
Operating Expense
$ 115.27M$ 116.18M$ 93.81M$ 50.78M$ 46.90M$ 26.82M
Operating Income
$ -73.60M$ -75.48M$ -60.42M$ -25.70M$ -46.24M$ -28.59M
Net Non Operating Interest Income Expense
$ 757.00K$ 284.00K$ 510.00K$ 1.40M$ 1.79M$ -1.78M
Other Income Expense
$ 19.27M$ 20.75M$ 18.61M$ -22.87M$ 27.63M$ -9.71M
Pretax Income
$ -53.57M$ -54.45M$ -41.31M$ -47.17M$ -16.82M$ -40.07M
Tax Provision
-$ 0.00$ 8.00K$ 1.00K$ 1.00K$ 1.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -53.57M$ -54.45M$ -41.31M$ -47.17M$ -16.82M$ -40.07M
Basic EPS
$ -0.41$ -0.44$ -0.45$ -0.51$ -0.24$ -0.97
Diluted EPS
$ -0.45$ -0.50$ -0.68$ -0.51$ -0.75$ -0.97
Basic Average Shares
$ 526.15M$ 124.47M$ 112.53M$ 91.08M$ 71.14M$ 41.43M
Diluted Average Shares
$ 527.59M$ 125.14M$ 114.48M$ 91.08M$ 72.39M$ 41.43M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 115.27M$ 116.18M$ 95.22M$ 53.45M$ 51.16M$ 30.21M
Net Income From Continuing And Discontinued Operation
$ -53.57M$ -54.45M$ -41.31M$ -47.17M$ -16.82M$ -40.07M
Normalized Income
$ -72.85M$ -75.21M$ -59.44M$ -24.30M$ -36.99M$ -32.98M
Interest Expense
------
EBIT
$ -73.60M$ -75.48M$ -60.42M$ -25.70M$ -46.24M$ -28.59M
EBITDA
$ -73.25M$ -75.16M$ -60.14M$ -25.59M$ -46.16M$ -28.53M
Currency in USD

MEI Pharma Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis